Autologous Dual-Target Car-T Cells Selected From The Predefined Target Library.
Advanced Unresectable
Beijing BiotechCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
180 Active assets in the Advanced Unresectable cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Catequentinib Nanfang Hospital, Southern Medical University | Phase 3 | BB |
Irinotecan M.D. Anderson Cancer Center | Phase 2 | BB |
Durvalumab OHSU Knight Cancer Institute | Phase 2 | BB |
Cediranib National Cancer Institute (NCI) | Phase 2 | BB |
Nivolumab CatalYm GmbH | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Autologous Dual-Target Car-T Cells Selected From The Predefined Target Library. is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →